April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas for the U.S. drug developer's experimental prostate cancer drug, Arvinas said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.44 USD | -1.60% | -4.20% | -23.62% |
05-08 | Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating | MT |
05-07 | Arvinas Shares Up After Q1 Net Loss Narrows | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
92.32 CHF | +1.97% | +4.94% | 208B | ||
31.44 USD | -1.60% | -4.20% | 2.15B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.62% | 2.15B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Novartis licenses Arvinas' cancer drug for up to $1 billion